Immutep Limited has received positive scientific advice from the European Medicines Agency (EMA) for the continued development of eftilagimod alpha (efti), the company's soluble LAG-3 protein and first-in-class MHC Class II agonist. The EMA advised that further toxicology studies are not needed for a future Marketing Authorisation Application (MAA). Similar advice was received from the US Food and Drug Administration (FDA). Immutep continues to interact with regulatory agencies regarding its expanding late-stage clinical pipeline with efti.